WCN26-6463 SAFETY AND PRELIMINARY EFFICACY FINDINGS FROM A PHASE 2A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF SETANAXIB IN PATIENTS WITH ALPORT SYNDROME